[
  {
    "ts": null,
    "headline": "Palantir and 4 Other Must-See Earnings Charts for Next Week",
    "summary": "Investors love these 5 popular companies. Will their earnings reports live up to their hype?",
    "url": "https://finnhub.io/api/news?id=1c66fcc9c6a1b87c7478568861ce9ddb85719e501a425d309b7469cf5331e69e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769727540,
      "headline": "Palantir and 4 Other Must-See Earnings Charts for Next Week",
      "id": 138302000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors love these 5 popular companies. Will their earnings reports live up to their hype?",
      "url": "https://finnhub.io/api/news?id=1c66fcc9c6a1b87c7478568861ce9ddb85719e501a425d309b7469cf5331e69e"
    }
  },
  {
    "ts": null,
    "headline": "Trump says Eli Lilly to build six US plants",
    "summary": "President Donald Trump said on Thursday ​that he has spoken to ‌the head of pharmaceutical company Eli Lilly ‌and that the company plans to build six plants in the country. \"I spoke with the head of ⁠Eli Lilly, who's ‌a fantastic guy, a star actually, he's a star, ‍very smart, and he told me he's building six plants in the United ​States, big ones,\" Trump said ‌during a cabinet meeting at the White House.",
    "url": "https://finnhub.io/api/news?id=ef2cdcf6dd9c2042f9f33cdd69fea8abeed2f44b185bafb9ca48552c5dd966c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769709927,
      "headline": "Trump says Eli Lilly to build six US plants",
      "id": 138298483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Donald Trump said on Thursday ​that he has spoken to ‌the head of pharmaceutical company Eli Lilly ‌and that the company plans to build six plants in the country. \"I spoke with the head of ⁠Eli Lilly, who's ‌a fantastic guy, a star actually, he's a star, ‍very smart, and he told me he's building six plants in the United ​States, big ones,\" Trump said ‌during a cabinet meeting at the White House.",
      "url": "https://finnhub.io/api/news?id=ef2cdcf6dd9c2042f9f33cdd69fea8abeed2f44b185bafb9ca48552c5dd966c6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive",
    "summary": "Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive",
    "url": "https://finnhub.io/api/news?id=9678fa53f94bb79f78aa3bf2544b0dec436122fc393a4acbdceec5fbb5871bc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769705462,
      "headline": "Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive",
      "id": 138300038,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9678fa53f94bb79f78aa3bf2544b0dec436122fc393a4acbdceec5fbb5871bc8"
    }
  },
  {
    "ts": null,
    "headline": "RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER",
    "summary": "Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.",
    "url": "https://finnhub.io/api/news?id=36e5e02f28a0cc54f326209ad1516f5fbd0987811b13ba825d1c1f9d79554895",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769698080,
      "headline": "RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER",
      "id": 138295584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.",
      "url": "https://finnhub.io/api/news?id=36e5e02f28a0cc54f326209ad1516f5fbd0987811b13ba825d1c1f9d79554895"
    }
  },
  {
    "ts": null,
    "headline": "How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity",
    "summary": "Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss space. The Swiss drug giant is working on four key drugs.",
    "url": "https://finnhub.io/api/news?id=22f23ccbfabdef98bfea715e0dddbed8d85a2057bfbda0d1206ce6e6c65153e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769696684,
      "headline": "How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity",
      "id": 138295585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss space. The Swiss drug giant is working on four key drugs.",
      "url": "https://finnhub.io/api/news?id=22f23ccbfabdef98bfea715e0dddbed8d85a2057bfbda0d1206ce6e6c65153e9"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results",
    "summary": "Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.",
    "url": "https://finnhub.io/api/news?id=27bd531e10f57af599efce14e8c7fc95a6357e0e878e38ba8e4ff749fdf209ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769695980,
      "headline": "Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results",
      "id": 138295596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.",
      "url": "https://finnhub.io/api/news?id=27bd531e10f57af599efce14e8c7fc95a6357e0e878e38ba8e4ff749fdf209ea"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead.",
    "summary": "This pharmaceutical giant is increasingly looking unstoppable.",
    "url": "https://finnhub.io/api/news?id=684fa025e9e2f33e2c041b7c5cc928200f1f4d6abfaf3044971794e2ff59ecc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769693100,
      "headline": "Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead.",
      "id": 138294602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This pharmaceutical giant is increasingly looking unstoppable.",
      "url": "https://finnhub.io/api/news?id=684fa025e9e2f33e2c041b7c5cc928200f1f4d6abfaf3044971794e2ff59ecc2"
    }
  },
  {
    "ts": null,
    "headline": "PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
    "summary": "Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs, performing surgeries, and processing insurance claims. That steady demand makes the sector attractive when investors want growth without the full roller coaster. But what if you could get healthcare exposure with a more concentrated bet ... PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
    "url": "https://finnhub.io/api/news?id=5ecd5f9a237559d9f1975a5686f05a175bfbd9f6aab58b80213020a4c2eac9c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769692834,
      "headline": "PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
      "id": 138295586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs, performing surgeries, and processing insurance claims. That steady demand makes the sector attractive when investors want growth without the full roller coaster. But what if you could get healthcare exposure with a more concentrated bet ... PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
      "url": "https://finnhub.io/api/news?id=5ecd5f9a237559d9f1975a5686f05a175bfbd9f6aab58b80213020a4c2eac9c2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Doubles U.S. Ad Spend on Wegovy, Ozempic",
    "summary": "Nearly $500 million spent through 2025 as weight-loss drug competition intensifies.",
    "url": "https://finnhub.io/api/news?id=37481db41e16a7ed13474b502717180ff7bfcbf64f4c09fbd58b4d823be33de8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769687881,
      "headline": "Novo Nordisk Doubles U.S. Ad Spend on Wegovy, Ozempic",
      "id": 138294603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nearly $500 million spent through 2025 as weight-loss drug competition intensifies.",
      "url": "https://finnhub.io/api/news?id=37481db41e16a7ed13474b502717180ff7bfcbf64f4c09fbd58b4d823be33de8"
    }
  },
  {
    "ts": null,
    "headline": "Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases",
    "summary": "Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (\"Lilly\") to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is c",
    "url": "https://finnhub.io/api/news?id=67a41cfbeeddb3fe760f61cce2758948d66e2a7097425ac7eb0d93f67395aa23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769686200,
      "headline": "Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases",
      "id": 138293778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (\"Lilly\") to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is c",
      "url": "https://finnhub.io/api/news?id=67a41cfbeeddb3fe760f61cce2758948d66e2a7097425ac7eb0d93f67395aa23"
    }
  },
  {
    "ts": null,
    "headline": "Moderna holds a ‘garage sale’; Roche defends obesity drug data",
    "summary": "Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA decision date.",
    "url": "https://finnhub.io/api/news?id=c04ed339fe7961afc6c1baff43dac33bcafca111f23048f74d307bea817c05de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769682000,
      "headline": "Moderna holds a ‘garage sale’; Roche defends obesity drug data",
      "id": 138306135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA decision date.",
      "url": "https://finnhub.io/api/news?id=c04ed339fe7961afc6c1baff43dac33bcafca111f23048f74d307bea817c05de"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A High-Yield Pharma At A Turning Point",
    "summary": "Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=ea773c0df2a52f5a28c6fe2da838c9ea509d4f6789a120078f8d1a8b0101e264",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769677200,
      "headline": "Pfizer: A High-Yield Pharma At A Turning Point",
      "id": 138295067,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202955977/image_1202955977.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=ea773c0df2a52f5a28c6fe2da838c9ea509d4f6789a120078f8d1a8b0101e264"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential",
    "summary": "The promising anti-inflammation target could be the next big thing in cardiovascular, other diseases.",
    "url": "https://finnhub.io/api/news?id=00daf425842e4d942f4df603ab89fb358927cb82213990dfc7fda089de83d6e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769673600,
      "headline": "Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential",
      "id": 138294604,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The promising anti-inflammation target could be the next big thing in cardiovascular, other diseases.",
      "url": "https://finnhub.io/api/news?id=00daf425842e4d942f4df603ab89fb358927cb82213990dfc7fda089de83d6e5"
    }
  },
  {
    "ts": null,
    "headline": "Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite",
    "summary": "The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation",
    "url": "https://finnhub.io/api/news?id=1a0c1acdc1ad41d1785d3f6e8d85e4d511b22157e3964309890d06902fc3351d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769668298,
      "headline": "Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite",
      "id": 138296568,
      "image": "https://image.cnbcfm.com/api/v1/image/108117484-1742300899522-gettyimages-1982130704-20090101240206-99-889432.jpeg?v=1753739868&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation",
      "url": "https://finnhub.io/api/news?id=1a0c1acdc1ad41d1785d3f6e8d85e4d511b22157e3964309890d06902fc3351d"
    }
  },
  {
    "ts": null,
    "headline": "Ivonescimab Included in FirstWord Pharma's \"The Drugs That Will Shape 2026\"",
    "summary": "Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled \"Spotlight On: The Drugs That Will Shape 2026\", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating f",
    "url": "https://finnhub.io/api/news?id=5a6dc000a1bead8ceb7afc2e4203e51f0051a65447bef4d88d28e701b85ba88a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769662260,
      "headline": "Ivonescimab Included in FirstWord Pharma's \"The Drugs That Will Shape 2026\"",
      "id": 138292030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled \"Spotlight On: The Drugs That Will Shape 2026\", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating f",
      "url": "https://finnhub.io/api/news?id=5a6dc000a1bead8ceb7afc2e4203e51f0051a65447bef4d88d28e701b85ba88a"
    }
  },
  {
    "ts": null,
    "headline": "Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.",
    "summary": "Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.",
    "url": "https://finnhub.io/api/news?id=ac20cc2a185006299e808d3584f961830004981752c7cdf3f465ccacace252c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769651400,
      "headline": "Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.",
      "id": 138291032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.",
      "url": "https://finnhub.io/api/news?id=ac20cc2a185006299e808d3584f961830004981752c7cdf3f465ccacace252c4"
    }
  }
]